MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Kodu・Aktsiate loetelu・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Suletud

SektorTervishoid

6.62 -1.63

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.58

Max

6.64

Põhinäitajad
By Trading Economics
Sissetulek	5.1M 5.1M
Müük	18M 163M
Kasumimarginaal	3.113
Töötajad	580
EBITDA	7.2M 28M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+212.22% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. nov 2025

Turustatistika
By TradingEconomics
Turukapital	-355M 1.5B
Eelmine avamishind	8.25
Eelmine sulgemishind	6.62

Uudiste sentiment

By Acuity

100%

356 / 371 Pingereas Healthcare

BioCryst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. okt 2025, 18:13 UTC

Suurimad hinnamuutused turgudel

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17. okt 2025, 17:05 UTC

Suurimad hinnamuutused turgudel

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18. okt 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

18. okt 2025, 07:00 UTC

Tulu

A Growing Nimby Movement Could Upend the Data Center Boom -- Barrons.com

17. okt 2025, 23:25 UTC

Omandamised, ülevõtmised, äriostud

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17. okt 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17. okt 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17. okt 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17. okt 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. okt 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17. okt 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17. okt 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17. okt 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17. okt 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17. okt 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. okt 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17. okt 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17. okt 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17. okt 2025, 16:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

17. okt 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. okt 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17. okt 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17. okt 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17. okt 2025, 15:56 UTC

Tulu

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17. okt 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

BioCryst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

212.22% tõus

12 kuu keskmine prognoos

Keskmine 20.7 USD 212.22%

Kõrge 30 USD

Madal 8 USD

Põhineb 10 Wall Streeti analüütiku instrumendi BioCryst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi BioCryst Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

356 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.